Could statins be a new therapeutic option for antiphospholipid syndrome patients?

Expert Review of Hematology

Volumn 6, Issue 2, 2013, Pages 115-117

  Erkan, Doruk ^a   Pierangeli, Silvia S ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

antiphospholipid antibodies; endothelial cells; pleitropic effects; statins

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; CARDIOLIPIN ANTIBODY; CD40 LIGAND; CHEMOKINE; CYTOKINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROMA; BRAIN ISCHEMIA; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; EDITORIAL; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; LONG TERM CARE; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84875924118     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.13.8     Document Type: Editorial

References (20)

1. Miyakis S, Lockshin MD, Atsumi T et al International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4(2), 295-306 (2006).
2. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin. Thromb. Hemost. 38(4), 305-321 (2012).
3. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al. Evidence based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody (aPL) positive patients: Report of a task force at the 13th International Congress on aPL. Lupus 20, 206-218 (2011).
4. Pierangeli SS, Erkan D Antiphospholipid syndrome treatment beyond anticoagulation: Are we there yet? Lupus 19(4), 475-485 (2010).
5. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84(3), 413-428 (1999).
6. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21, 1712-1719 (2001).
7. Sparrow CP, Burton CA, Hernandez M et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21(1), 115-121 (2001).
8. Sparrow CP, Burton CA, Hernandez M et al. Tremoli E. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in absence of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 22, 692-698 (2002).
9. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279(20), 1643-1650 (1998).
10. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann. Med. 32(3), 164-176 (2000).
11. Cortellaro M, Cofrancesco E, Arbustini E et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: The ATROCAP study. Thromb. Haemost. 88(1), 41-47 (2002).
12. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360(18), 1851-1861 (2009).
13. Ridker PM, Danielson E, Fonseca FA et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 373(9670), 1175-1182 (2009).
14. Meroni PL, Raschi E, Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 44(12), 2870-2878 (2001).
15. Ferrara DE, Liu X, Espinola RG et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 48(11), 3272-3279 (2003).
16. Ferrara DE, Swerlick R, Casper K et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J. Thromb. Haemost. 2(9), 1558-1563 (2004).
17. Martinez-Martinez LA, Amigo MC, Orozco A et al. Effect of rosuvastatin on VCAM-1 expression by HIVEC exposed to APS serum in an in vitro model. Clin. Exp. Rheumatol. 25, 18-19 (2007).
18. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J. Reprod. Immunol. 82(2), 126-131 (2009).
19. Cuadrado MJ, Lopez-Pedrera C, Aguirre A et al. Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins. Arth. Rheum. 56, S782 (2007).
20. Erkan D, Willis R, Vega J et al. An openlabel prospective pilot mechanistic study of fluvastatin in persistently antiphospholipid antibody-positive patients. Arth. Rheum. 64, S1034-S1035 (2012).